{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:01:20Z","timestamp":1764331280250,"version":"3.40.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2","KL2TR002381","UL1TR002378","R25GM143298"],"award-info":[{"award-number":["KL2","KL2TR002381","UL1TR002378","R25GM143298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","award":["2022-04-007"],"award-info":[{"award-number":["2022-04-007"]}],"id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016220","name":"Georgia Clinical and Translational Science Alliance","doi-asserted-by":"publisher","award":["UL1TR002378","KL2TR002381"],"award-info":[{"award-number":["UL1TR002378","KL2TR002381"]}],"id":[{"id":"10.13039\/100016220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.molmed.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:08:14Z","timestamp":1738274894000},"page":"388-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery"],"prefix":"10.1016","volume":"31","author":[{"given":"Brett","family":"Henshey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-8960","authenticated-orcid":false,"given":"Kecheng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Boulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.01.004_bb0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/gt.2015.47","article-title":"Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors","volume":"22","author":"Hoyng","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/hum.2012.094","article-title":"Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1","volume":"24","author":"Prabhakar","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/1566523220666200806111451","article-title":"NF1, neurofibromin and gene therapy: prospects of next-generation therapy","volume":"20","author":"Cui","year":"2020","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0020","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1073\/pnas.88.21.9658","article-title":"Identification of the neurofibromatosis type 1 gene product","volume":"88","author":"Gutmann","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.01.004_bb0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/humu.21387","article-title":"Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: importance of copy neutral LOH","volume":"32","author":"Garcia-Linares","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.molmed.2025.01.004_bb0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12935-020-01570-8","article-title":"Advancement in research and therapy of NF1 mutant malignant tumors","volume":"20","author":"Tao","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.molmed.2025.01.004_bb0035","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The diagnosis and management of neurofibromatosis type 1","volume":"103","author":"Ly","year":"2019","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.molmed.2025.01.004_bb0040","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.3390\/cancers13236032","article-title":"Targeted therapies for the neurofibromatoses","volume":"13","author":"Sanchez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.01.004_bb0045","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2025.01.004_bb0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","article-title":"Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848","volume":"102","author":"Koczkowska","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2025.01.004_bb0060","article-title":"Impacts of NF1 gene mutations and genetic modifiers in neurofibromatosis type 1","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0065","first-page":"354","article-title":"The neurofibromatoses","volume":"117","author":"Farschtschi","year":"2020","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.molmed.2025.01.004_bb0070","first-page":"i107","article-title":"Management of cutaneous neurofibroma: current therapy and future directions","volume":"2","author":"Chamseddin","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.molmed.2025.01.004_bb0075","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jaad.2020.07.105","article-title":"Neurofibromatosis type 1: new developments in genetics and treatment","volume":"84","author":"Wilson","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0080","series-title":"Diagnostic Assessment and Treatment of Peripheral Nerve Tumors","first-page":"3","article-title":"Epidemiology of peripheral nerve sheath tumors","author":"Jack","year":"2021"},{"key":"10.1016\/j.molmed.2025.01.004_bb0085","first-page":"101","article-title":"Advanced pharmacological therapies for neurofibromatosis type 1-related tumors","volume":"91","author":"Foiadelli","year":"2020","journal-title":"Acta Biomed"},{"year":"2020","series-title":"Multidisciplinary Approach to Neurofibromatosis Type 1","author":"Tadini","key":"10.1016\/j.molmed.2025.01.004_bb0090"},{"key":"10.1016\/j.molmed.2025.01.004_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-021-01032-y","article-title":"Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib","volume":"23","author":"Galvin","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.molmed.2025.01.004_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/IIO.0000000000000363","article-title":"Expression cassette design and regulation of transgene expression","volume":"61","author":"Keravala","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.molmed.2025.01.004_bb0105","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2025.01.004_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2022.06.003","article-title":"A systematic review of recent and ongoing clinical trials in patients with the neurofibromatoses","volume":"134","author":"Acar","year":"2022","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0115","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.3390\/ijms22115850","article-title":"Current understanding of neurofibromatosis type 1, 2, and schwannomatosis","volume":"22","author":"Tamura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.01.004_bb0120","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.molmed.2025.01.004_bb0125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/EBC20170053","article-title":"The genetic basis of disease","volume":"62","author":"Jackson","year":"2018","journal-title":"Essays Biochem."},{"key":"10.1016\/j.molmed.2025.01.004_bb0130","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.01.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00780-23","article-title":"Structural and antigenic characterization of the avian adeno-associated virus capsid","volume":"97","author":"Hsi","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0140","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0145","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers12071889","article-title":"Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: current status and future perspectives","volume":"12","author":"Hacker","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.01.004_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00773-21","article-title":"Improved genome packaging efficiency of adeno-associated virus vectors using rep hybrids","volume":"95","author":"Mietzsch","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0155","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1038\/s41467-021-26485-4","article-title":"The membrane associated accessory protein is an adeno-associated viral egress factor","volume":"12","author":"Elmore","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.01.004_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/hum.2019.274","article-title":"Adeno-associated virus serotype-specific inverted terminal repeat sequence role in vector transgene expression","volume":"31","author":"Earley","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsb.2021.107795","article-title":"Comparative structural, biophysical, and receptor binding study of true type and wild type AAV2","volume":"213","author":"Bennett","year":"2021","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41434-019-0080-9","article-title":"Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors","volume":"26","author":"Bai","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02694-1","article-title":"Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery","volume":"11","author":"Kagiava","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2025.01.004_bb0195","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/ijms23020819","article-title":"Schwannoma gene therapy via adeno-associated viral vector delivery of apoptosis-associated speck-like protein containing CARD (ASC): preclinical efficacy and safety","volume":"23","author":"Ahmed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.01.004_bb0200","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Nasso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.molmed.2025.01.004_bb0205","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2022.2012148","article-title":"Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders","volume":"22","author":"Marrone","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0210","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3390\/cells9112365","article-title":"Neurofibromin structure, functions and regulation","volume":"9","author":"Bergoug","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2025.01.004_bb0215","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0220","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneumeth.2019.05.007","article-title":"Developing myelin specific promoters for schwannoma gene therapy","volume":"323","author":"Ahmed","year":"2019","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.molmed.2025.01.004_bb0225","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1044-7431(03)00246-X","article-title":"Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons","volume":"24","author":"Maier","year":"2003","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.molmed.2025.01.004_bb0230","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1471-4159.2004.02745.x","article-title":"Characterization of a Schwann cell enhancer in the myelin basic protein gene","volume":"91","author":"Taveggia","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2025.01.004_bb0235","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1073\/pnas.96.5.2296","article-title":"Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease","volume":"96","author":"Daly","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.01.004_bb0240","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/mt.2012.280","article-title":"A comprehensive review of retinal gene therapy","volume":"21","author":"Boye","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11886-012-0333-3","article-title":"Gene therapy for heart failure: where do we stand?","volume":"15","author":"Naim","year":"2013","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.molmed.2025.01.004_bb0250","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2025.01.004_bb0255","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.molmed.2025.01.004_bb0260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2025.01.004_bb0265","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.01.004_bb0270","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/brainsci10020119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.molmed.2025.01.004_bb0275","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41434-022-00363-0","article-title":"Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies","volume":"30","author":"Burdett","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0285","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"Buning","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2025.01.004_bb0290","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","article-title":"Adeno-associated virus (AAV) vectors: rational design strategies for capsid engineering","volume":"7","author":"Lee","year":"2018","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.molmed.2025.01.004_bb0295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.virol.2008.08.027","article-title":"Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression","volume":"381","author":"Zhong","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.molmed.2025.01.004_bb0300","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1159\/000445646","article-title":"Tyrosine mutation in AAV9 capsid improves gene transfer to the mouse lung","volume":"39","author":"Martini","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.molmed.2025.01.004_bb0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hgtb.2012.194","article-title":"Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo","volume":"24","author":"Gabriel","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.molmed.2025.01.004_bb0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0315","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2018.03.004","article-title":"A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates","volume":"9","author":"Wang","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2025.01.004_bb0320","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/12491","article-title":"Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2","volume":"5","author":"Girod","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.01.004_bb0325","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1089\/104303401750476212","article-title":"Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors","volume":"12","author":"Shi","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0330","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno-associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Nat. Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0340","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/mt.2008.167","article-title":"DNA shuffling of adeno-associated virus yields functionally diverse viral progeny","volume":"16","author":"Koerber","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0345","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/gt.2015.74","article-title":"AAV ancestral reconstruction library enables selection of broadly infectious viral variants","volume":"22","author":"Santiago-Ortiz","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0350","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","article-title":"In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector","volume":"12","author":"Zinn","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2025.01.004_bb0355","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0360","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1110\/ps.0306603","article-title":"Library analysis of SCHEMA-guided protein recombination","volume":"12","author":"Meyer","year":"2003","journal-title":"Protein Sci."},{"key":"10.1016\/j.molmed.2025.01.004_bb0365","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymthe.2017.09.006","article-title":"In vivo selection of a computationally designed SCHEMA AAV library yields a novel variant for infection of adult neural stem cells in the SVZ","volume":"26","author":"Ojala","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2025.01.004_bb0370","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.molmed.2025.01.004_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674021","article-title":"Overcoming immunological challenges limiting capsid-mediated gene therapy with machine learning","volume":"12","author":"Wec","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0380","article-title":"Optimal trade-off control in machine learning-based library design, with application to adeno-associated virus (AAV) for gene therapy","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2025.01.004_bb0385","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0390","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/iep.12478","article-title":"Clinical applications of gene therapy for rare diseases: a review","volume":"104","author":"Papaioannou","year":"2023","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0395","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2016.07.006","article-title":"Systemic delivery of adeno-associated viral vectors","volume":"21","author":"Duan","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.molmed.2025.01.004_bb0400","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","article-title":"Neurofibromin and suppression of tumorigenesis: beyond the GAP","volume":"41","author":"Mo","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2025.01.004_bb0405","first-page":"i40","article-title":"Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives","volume":"2","author":"Prudner","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.molmed.2025.01.004_bb0410","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.21873\/anticanres.14136","article-title":"New frontiers in therapy of peripheral nerve sheath tumors in patients with neurofibromatosis type 1: latest evidence and clinical implications","volume":"40","author":"Marjanska","year":"2020","journal-title":"Anticancer Res."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:53:30Z","timestamp":1744448010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1471491425000048"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.01.004","relation":{},"ISSN":["1471-4914"],"issn-type":[{"type":"print","value":"1471-4914"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}